Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deficiency of the interleukin-36 receptor antagonist dramatically improved by secukinumab.

The Journal of dermatology - 1 Oct 2018

Kinoshita Manao, Okamoto Takashi, Sano Shinya, Mitsui Hiroshi, Takeichi Takuya, Sugiura Kazumitsu, Akiyama Masashi, Shimada Shinji, Kawamura Tatsuyoshi

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interleukins

Share to Psoriasis

Share to Severity of Illness Index

Share to Treatment Outcome

Source

Identifiers

PMID: 29665114
DOI: 10.1111/1346-8138.14330

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deficiency of the interleukin-36 receptor antagonist dramatically improved by secukinumab.PMID 29665114Read ↗

SARS-CoV-2 infection inducing severe flare up of Deficiency of Interleukin Thirty-six (IL-36) Receptor Antagonist (DITRA) resulting from a mutation invalidating the activating cleavage site of the IL-36 receptor antagonist.Semantic proximity Read ↗

Impetigo herpetiformis with IL-36RN mutation successfully treated with secukinumab.Semantic proximity Read ↗

Response to Interleukin (IL)-17 Inhibition in an Adolescent With Severe Manifestations of IL-36 Receptor Antagonist Deficiency (DITRA).Semantic proximity Read ↗

Cutaneous findings and treatments in deficiency of interleukin-36 receptor antagonist (DITRA): A review of the literature.Semantic proximity Read ↗

Molecular determinants of agonist and antagonist signaling through the IL-36 receptor.Semantic proximity Read ↗

Analysis of Anakinra therapy for the Deficiency of Interleukin-1 Receptor Antagonist through Clinical EvidenceSemantic proximity Read ↗

Biology of IL-36 cytokines and their role in diseaseSemantic proximity Read ↗

The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases.Semantic proximity Read ↗

Recurrence of impetigo herpetiformis carrying compound heterozygous mutations in IL36RN after remission with secukinumab.Semantic proximity Read ↗

Restoration of MBL-deficiency: redefining the safety, efficacy and viability of MBL-substitution therapy.Semantic proximity Read ↗

Extending the clinical and immunological phenotype of human interleukin-21 receptor deficiency.Semantic proximity Read ↗

Relieving job: Dupilumab in autosomal dominant STAT3 hyper-IgE syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.